Summary: EnsoData raised $20 million in Series B funding led by Questa Capital to scale its FDA-cleared AI sleep medicine platform and grow its commercial team, aiming to increase access to diagnostic and therapeutic solutions for sleep apnea.
Key takeaways:
- EnsoData has secured $20 million in Series B financing, led by Questa Capital with participation from existing investors including Inspire Medical Systems.
- The funding will support expansion of EnsoData’s AI-powered sleep medicine tools and scaling of its U.S. commercial operations.
- The company aims to address underdiagnosis and undertreatment in sleep apnea by offering more accessible and efficient diagnostic and therapeutic pathways.
- A new chief commercial officer, Bobby Cockrill, has joined to lead strategic sales and operations as part of the commercial expansion strategy.
EnsoData today announced a $20 million Series B financing led by Questa Capital. This new capital will enable EnsoData to accelerate adoption of its artificial intelligence (AI)-powered sleep medicine solutions.
“Traditional approaches in sleep medicine have left nearly 80% of patients undiagnosed and, of the 20% that are positively diagnosed, only 1 in 2 will be successfully treated,” says Justin Mortara, PhD, president and CEO of EnsoData, in a release. “We need to expand patient access with simpler and more economic testing while embracing new approaches for sleep apnea therapies to improve this reality. EnsoData’s AI solutions are uniquely positioned to do both, and this Series B fundraise will allow us to rapidly scale our commercial team to deliver the next wave of AI-driven healthcare solutions.”
The EnsoData team is already growing, with the recent addition of a new chief commercial officer, Bobby Cockrill, MBA. “The appointment of Bobby is our first step toward establishing a substantial US commercial team. His deep experience in diagnostics and managing strategic sales and sales operations are already having an exciting impact,” Mortara says.
Brian Butler, partner at Questa Capital, says in a release, “EnsoData has built a uniquely comprehensive platform that integrates disruptive, FDA-cleared clinical technologies across a complete care pathway. The team’s design discipline emphasizes usability and interoperability, an approach that has established EnsoData as a leader in sleep while positioning the company for future growth in adjacent specialties. We are thrilled to partner with such an experienced team at the helm of an innovative technology company.”
In addition to Questa Capital, existing investors participated in the Series B, including Zetta Venture Partners, Venture Investors Health Fund, Supermoon Capital, and Inspire Medical Systems.
We recommend for you:
.
